P-Values

Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.

At P-Values, you’ll find updates, perspective, insights and information from staff and partners working on the frontlines of research, advocacy and implementation. P-value is a statistical term for the probability that a trial result is reliable and not the outcome of chance. 

Featured

Blog Post

AVAC and Access Bridge Applaud Monthly PrEP Pill Access Announcement; Call for Speed, Scale and Equity in Future Monthly Oral Alimatravir Introduction

AVAC and Access Bridge applaud Merck’s announcement today that it has granted seven direct licenses to generic manufacturers to produce their investigational monthly pill for HIV prevention, known as MK-8527, or alimatravir, while Phase 3 clinical trials are still enrolling. “Today’s news reflects truly positive momentum in future access to alimatravir for PrEP, if proven safe and effective,” said Mitchell Warren, AVAC’s executive director.

Read more

Blog Post

CASPR Impact Report: Celebrating Growth, Inspiring the Future

AVAC is proud to release the CASPR Impact Report: Celebrating Growth, Inspiring the Future, celebrating what is possible when long-term investment in African leadership, partnerships and coalition-based advocacy is matched with shared purpose. CASPR, the Coalition to Accelerate and Support Prevention Research, proved that community-led coalitions are central to turning innovation into action, and ensuring that advances in HIV prevention are shaped by the people they are meant to serve.

Read more

Blog Post

Global Health Watch: 500,000 oppose White House grant rule, CDC & PEPFAR's future, global health transition strategy, Gawande & AIDS 2026, issue 77

More than half a million comments were submitted in response to the White House’s proposal to politicize federal research grants – with a significant majority opposing it. At the same time, questions mounted over the future of the CDC, PEPFAR, and the Administration’s vision for transitioning US global health programs. This week also features reflections from former USAID global health leader Atul Gawande on the human cost of dismantling USAID and the likely discussions ahead at AIDS 2026 on the consequences of US policy changes for HIV programs and global health.

Read more

Filter by

Reset filters

P-Values

showing 1-10 of 1245

AVAC and Access Bridge Applaud Monthly PrEP Pill Access Announcement; Call for Speed, Scale and Equity in Future Monthly Oral Alimatravir Introduction

AVAC and Access Bridge applaud Merck’s announcement today that it has granted seven direct licenses to generic manufacturers to produce their investigational monthly pill for HIV prevention, known as MK-8527, or alimatravir, while Phase 3 clinical trials are still enrolling. “Today’s news reflects truly positive momentum in future access to alimatravir for PrEP, if proven safe and effective,” said Mitchell Warren, AVAC’s executive director.

July 2026

CASPR Impact Report: Celebrating Growth, Inspiring the Future

AVAC is proud to release the CASPR Impact Report: Celebrating Growth, Inspiring the Future, celebrating what is possible when long-term investment in African leadership, partnerships and coalition-based advocacy is matched with shared purpose. CASPR, the Coalition to Accelerate and Support Prevention Research, proved that community-led coalitions are central to turning innovation into action, and ensuring that advances in HIV prevention are shaped by the people they are meant to serve.

July 2026

Global Health Watch: 500,000 oppose White House grant rule, CDC & PEPFAR’s future, global health transition strategy, Gawande & AIDS 2026, issue 77

More than half a million comments were submitted in response to the White House’s proposal to politicize federal research grants – with a significant majority opposing it. At the same time, questions mounted over the future of the CDC, PEPFAR, and the Administration’s vision for transitioning US global health programs. This week also features reflections from former USAID global health leader Atul Gawande on the human cost of dismantling USAID and the likely discussions ahead at AIDS 2026 on the consequences of US policy changes for HIV programs and global health.

July 2026

The Legacy of CASPR: Building the Future of Africa-led HIV Prevention Advocacy 

The future of HIV prevention will depend not only on scientific breakthroughs, but on advocacy to bring those breakthroughs to communities to achieve impact. With global health undergoing profound change, the way forward requires new models of collaboration that are community-led, locally owned and sustainably funded. The Coalition to Accelerate and Support Prevention Research (CASPR) offers one such model for the field as we collectively work to end the HIV epidemic.

July 2026

AVAC’s Guide to AIDS 2026

The AIDS 2026 conference in Rio de Janeiro, Brazil comes at a defining moment for the global HIV response. AVAC’s resources aim to help those attending AIDS 2026—and those following from afar—navigate the discussion and debate in and around Rio.

July 2026

Global Health Watch: Latest on White House OMB Federal Rx Grant Proposal, Global Fund Gains Stability, New Model for GH Partnerships

As the comment period to oppose the White House Office of Management and Budget’s (OMB) proposal to give political appointees greater authority over federal research grants closes next Monday, the Global Fund avoided new ideological restrictions on US funding even as it prepares for a new Executive Director. And new articles and analyses of US bilateral health agreements under the “America First Global Health Strategy” suggest the Administration’s vision for global health is shifting from supporting epidemic control to managing country transitions.

Prevention Option:

Topic:

July 2026

Best of AVAC’s Advocacy Guides

To help advocates stay informed and engaged, AVAC has curated a collection of its Advocates’ Guides ahead of the AIDS 2026 conference. Covering the science, policy, implementation and advocacy conversations shaping the future of the HIV/AIDS response and developed with partners across the field, these guides help translate complex science and policy to help inform advocacy before, during and after the conference.

Prevention Option:

Topic:

July 2026

Global Health Watch: Global Governance Shifts, ACIP Charter + Vaccine Policy, PEPFAR Transition

As many in the United States pause to commemorate Independence Day – and, hopefully, re-commit to the fundamental principles of democracy – the global health community continues to navigate the far-reaching effects of US policy decisions. Institutions are changing, governance is being redefined and the systems that have underpinned the global HIV response are being reshaped. This issue covers developments in global health governance, the continued restructuring of US vaccine policy and growing concerns that PEPFAR’s transition is outpacing the systems needed to sustain it.

July 2026

Protecting Science. Advancing HIV Prevention. Preparing for What’s Next | New AVAC Resources

Global health is being reshaped by rapid geopolitical shifts, scientific breakthroughs and the growing role of artificial intelligence — creating both new opportunities and new challenges. Translating scientific breakthroughs into impact requires protecting research, advancing equitable access and ensuring communities are at the center. Explore AVAC’s latest resources to help navigate and shape what comes next.

July 2026

From Anticipation to Action: The Civil Society Advocates’ Checklist for Lenacapavir for PrEP 

The most recent option in HIV prevention is injectable lenacapavir for PrEP – a six-monthly subcutaneous injection. To ensure community leadership is at the center of this rollout, the Advocates’ Checklist for Lenacapavir for PrEP Introduction helps CSOs and global health advocates pressure-test government commitments, map implementation bottlenecks and demand equitable access.

Prevention Option:

Topic:

June 2026

showing 1-10 of 1245

Explore More News and Communications

P-Values Blog

Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.

Advocates Network

AVAC’s email list for organization and individuals interested in timely updates and critical perspectives on developments in biomedical HIV prevention.

Weekly News Digest

A comprehensive round-up of HIV prevention media coverage and scientific publications.

PxPulse

Each month this podcast uses interviews, discussion and first-person reflections to explore vital topics confronting the field of HIV prevention research.

PxWire

PxWire is AVAC’s quarterly update on biomedical HIV prevention. Each issue highlights key developments, challenges and opportunities, and features a centerspread infographic that provides a visual tool for framing these issues.

Pandemic Watch

Pandemic Watch is a curated news digest on the latest pandemic prevention, preparedness, and response (PPPR) news and resources.

Press Releases

A collection of official statements from AVAC.

AVAC in the News

Media clippings featuring AVAC, its staff and close partners in the news media.